What is Attralus?
Attralus is a specialized biopharmaceutical enterprise dedicated to the development of transformative medicines for systemic amyloidosis, a group of rare and serious diseases characterized by the accumulation of misfolded proteins. By leveraging a sophisticated platform designed to target and clear amyloid deposits, the company is positioned at the intersection of precision medicine and protein homeostasis. Its market position is defined by a commitment to scientific rigor and the pursuit of novel therapeutic modalities that aim to improve patient outcomes in conditions where current standard-of-care options remain limited. The company's focus on systemic amyloidosis places it within a high-growth niche of the biopharma industry, attracting institutional interest from firms specializing in long-term healthcare value creation.
How much funding has Attralus raised?
Attralus has raised a total of $141M across 2 funding rounds:
Series A
$25M
Series B
$116M
Series A (2020): $25M with participation from venBio Partners
Series B (2021): $116M led by Janus Henderson Investors, Redmile Group, Logos Capital, and Samsara BioCapital
Key Investors in Attralus
venBio Partners
A life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Janus Henderson Investors
A global investment management firm providing a broad range of investment solutions and advisory services, focused on achieving strong long-term outcomes through disciplined research.
Redmile Group
A New York-based firm operating within the venture capital and private equity industry, known for its strategic focus on high-growth healthcare and biotechnology enterprises.
What's next for Attralus?
With the successful closure of its recent financing, Attralus is poised to accelerate its clinical development programs and expand its research capabilities. The strategic deployment of this capital will likely focus on advancing its lead candidates through human trials, optimizing manufacturing processes, and strengthening its intellectual property portfolio. As the company matures, the focus will shift toward demonstrating clinical efficacy and safety, which are essential precursors to potential regulatory filings and long-term commercialization. The backing from top-tier life sciences investors suggests a clear path toward scaling operations and potentially exploring strategic partnerships that could further validate its therapeutic platform in the global healthcare market.
See full Attralus company page